An Increased Risk of Metabolic Syndrome in Type 2 Diabetes Mellitus Patients Is Suggested by a High TG/HDL Ratio-A Retrospective Study

Background: The prevalence of cardiovascular events and the risk of mortality are higher among patients with Metabolic syndrome (MetS), and the risk factors include central obesity, increased blood pressure, increased fasting blood glucose (FBG) levels and abnormal blood lipids. Early diagnosis of MetS and timely intervention can prevent unnecessary complications related to its progression and help reduce the risk of Cardiovascular disorders (CVD). Purpose: The purpose of this EHR-based real-world study was to identify the relationship between Triglyceride/High-density lipoprotein cholesterol (TG/HDL-C) ratio and metabolic syndrome. Methods: Participants in the trial must have had type 2 diabetes mellitus for at least six months and must be presenting for routine treatment in one of 14 centres around the nation. Data on medical history, diabetes complications, medications, and laboratory values were gathered using an EMR (MEDEVA) integrated research proforma, and the study period was for six months (March-August 2022). Clinical and statistical professionals at MEDEVA combined anonymized data and conducted analyses using Python 3.6 (pandas, scikit-learn, SciPy for exploratory data analysis, and Matplotlib for exploratory visualisation), SPSS version 26 (statistical analysis). Results: Of the 372 patients with Type 2 Diabetes Mellitus, 278 had Metabolic Syndrome (MetS), and 94 did not have MetS. The TG/HDL ratio was significantly higher for the group with MetS (5.1) than the group without MetS (2.7). As a next step, to avoid potential confounding, the sample was adjusted for BMI and age, i.e., covariate matching was done. The TG/HDL ratio continued to be higher for the group with MetS (5.4) than the group without MetS (2.7). Conclusion: We discovered a strong link between metabolic syndrome and the TG/HDL-C ratio. A high TG/HDL ratio indicates an increased risk of developing metabolic syndrome. Disclosure A.K.Saxena: None. S.S.Dariya: None. A.Patil: None. S.K.Patra: None. D.Kumar: None. R.Regulla: None. M.Gupta: None. M.Lakshmanan: None. R.Sheohare: None. B.Patni: None. M.Aslam: None. A.Maheshwari: None. N.K.Singh: None. V.S.Hiremath: None.